<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02734966</url>
  </required_header>
  <id_info>
    <org_study_id>ZTDQ01341301</org_study_id>
    <nct_id>NCT02734966</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection in Subjects With Acute Drug-induced Liver Injury</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Active Control Phase II Study to Investigate Multiple Dosage and Treatments of Magnesium Isoglycyrrhizinate Injection to Cure the Acute Drug-induced Liver Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety, effective dosage and treatment of
      Magnesium Isolycyrrhizinate Injection to cure the acute drug-induced liver injury compared
      with the Tiopronin Injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pharmacology research shows that Magnesium Isoglycyrrhizinate could significantly
      decrease the elevation of ALT and AST coursed by carbon tetrachloride, D-galactosamine and
      Thioacetamide. It could also significantly reduce the injury on the liver coursed by
      D-galacosamine and immunologic factors. Magnesium Isoglycyrrhizinate with strong
      anti-inflammatory effect could protect the liver cell and improve the liver function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of ALT normalization at week 4 of treatment</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>rates of ALT normalization at weeks 1, 2, and 3 of treatment</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of ALT at weeks 1, 2, 3 and 4 of treatment;</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of AST at weeks 1, 2, 3 and 4 of treatment.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Drug-Induced Liver Injury</condition>
  <arm_group>
    <arm_group_label>arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lower dose： Magnesium Isoglycyrrhizinate injection 100mg OD for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>higher dose：Magnesium Isoglycyrrhizinate injection 200mg OD for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiopronin Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiopronin Injection 200mg OD for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Isoglycyrrhizinate Injection 100mg OD</intervention_name>
    <description>Magnesium Isoglycyrrhizinate Injection 100mg OD</description>
    <arm_group_label>arm 1</arm_group_label>
    <other_name>Jiangsu Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Isoglycyrrhizinate Injection 200mg OD</intervention_name>
    <description>Magnesium Isoglycyrrhizinate Injection 200mg OD for 4 weeks</description>
    <arm_group_label>arm 2</arm_group_label>
    <other_name>Jiangsu Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiopronin Injection</intervention_name>
    <description>Tiopronin Injection 200mg OD</description>
    <arm_group_label>Tiopronin Injection</arm_group_label>
    <other_name>Jinan Limin Pharmaceutical Co., Ltd.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  RACUM ≥6

          -  ALTs ≥2ULN, but TBiL is ≤ 3 ULN.It may be associated with AST or ALP or TBiL exceed
             the upper limit of normal

          -  Liver biochemical abnormalities duration of no more than three months

          -  Patients need to fully understand and sign the inform consent form.

        Exclusion Criteria:

          -  The liver injury is caused by other diseases, such as virus hepatitis, alcohol and
             non-alcohol fatty liver disease or the autoimmune liver disease.

          -  The patients with the acute hepatic failure or hepatic decompensation, such as hepatic
             encephalopathy, ascites, albumin is ≤ 35g/L, prothrombin time is elongated more than 2
             seconds compared to its normal range.

          -  The value of the TBiL is &gt; 3ULN.

          -  The value of serum creatinine is &gt; 1.5ULN.

          -  Patients who have severe organic diseases on heart, lungs, brain, kidney and
             gastrointestinal tract.

          -  Patients who are taking the drugs that might interfere the trial.

          -  Patients who are allergic or intolerant to the study drug.

          -  Patients who are not able to express the chief complaint, for example, the patients
             with psychosis and severe neurosis.

          -  Patients who are compliant with protocol.

          -  Women who are pregnant, breast-feeding or with childbearing potential.

          -  Patients who have attended other clinical trials within 3 months.

          -  Not appropriate to be included after assessing by the investigators.

        ULN=Upper Limited Normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minde Zeng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Chest Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Pulmonary Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>85 Hospital of People's Liberation Army</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renji Hospital Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Chinese and Western Medicine Hospital of Zhejiang Province</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997 Sep;26(3):664-9.</citation>
    <PMID>9303497</PMID>
  </reference>
  <reference>
    <citation>Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology. 2006 Mar;43(3):618-31.</citation>
    <PMID>16496329</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>September 25, 2016</last_update_submitted>
  <last_update_submitted_qc>September 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-Induced</keyword>
  <keyword>Acute Liver Injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Chemical and Drug Induced Liver Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

